Literature DB >> 24368930

Primary prophylaxis for cryptococcal meningitis and impact on mortality in HIV: a systematic review and meta-analysis.

Richard Ssekitoleko1, Moses R Kamya2, Arthur L Reingold3.   

Abstract

AIM: To determine the role of primary antifungal prophylaxis in the prevention of cryptococcal meningitis and all-cause mortality in advanced HIV infection. MATERIALS &
METHODS: This was a systematic review and meta-analysis of randomized trials and observational studies. Google Scholar™, PubMed and Embase databases were searched for relevant studies. Quality was assessed using different criteria, depending on study type. Publication bias was assessed and subgroup and sensitivity analyses were performed. When the results of the meta-analysis were homogeneous, the fixed-effects model was used; when the results of the meta-analysis were heterogenous, the random effects model was used.
RESULTS: Primary prophylaxis prevented cryptococcal meningitis but did not confer protection against overall mortality, although there was evidence of a reduction in cryptococcal-specific mortality in resource-limited settings.
CONCLUSION: Primary antifungal prophylaxis should be recommended in patients with advanced HIV infection in resource-limited settings with a high incidence of cryptococcal meningitis.

Entities:  

Keywords:  advanced HIV infection; all-cause mortality; cryptococcal meningitis; fluconazole; itraconazole; prevention of cryptococcal meningitis; primary antifungal prophylaxis; resource-limited settings

Year:  2013        PMID: 24368930      PMCID: PMC3869998          DOI: 10.2217/fvl.13.71

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  47 in total

Review 1.  Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection.

Authors:  J A Kovacs; H Masur
Journal:  N Engl J Med       Date:  2000-05-11       Impact factor: 91.245

2.  Does fluconazole prevent cryptococcal meningitis in human immunodeficiency virus-infected patients?

Authors:  C Pradier; E Bernard; C Lubick; M Toussaint-Gari; Y Pinier; J Durant; V Mondain; Y Le Fichoux; P Dellamonica
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

3.  Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Authors:  D S McKinsey; L J Wheat; G A Cloud; M Pierce; J R Black; D M Bamberger; M Goldman; C J Thomas; H M Gutsch; B Moskovitz; W E Dismukes; C A Kauffman
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

4.  Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.

Authors:  David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

5.  A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection.

Authors:  D E Smith; J Bell; M Johnson; M Youle; B Gazzard; S Tchamouroff; G Frechette; W Schlech; S Miller; D Spencer; W Seifert; M Peeters; K De Beule
Journal:  HIV Med       Date:  2001-04       Impact factor: 3.180

6.  A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency.

Authors:  P Chetchotisakd; S Sungkanuparph; B Thinkhamrop; P Mootsikapun; P Boonyaprawit
Journal:  HIV Med       Date:  2004-05       Impact factor: 3.180

7.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

8.  Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda.

Authors:  M Okongo; D Morgan; B Mayanja; A Ross; J Whitworth
Journal:  Int J Epidemiol       Date:  1998-08       Impact factor: 7.196

Review 9.  The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection.

Authors:  M R Nelson; M Fisher; J Cartledge; T Rogers; B G Gazzard
Journal:  AIDS       Date:  1994-05       Impact factor: 4.177

10.  A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.

Authors:  S A Bozzette; R A Larsen; J Chiu; M A Leal; J Jacobsen; P Rothman; P Robinson; G Gilbert; J A McCutchan; J Tilles
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

View more
  8 in total

Review 1.  Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings.

Authors:  Sarah Lofgren; Mahsa Abassi; Joshua Rhein; David R Boulware
Journal:  Expert Rev Anti Infect Ther       Date:  2017-02-09       Impact factor: 5.091

Review 2.  The war on cryptococcosis: A Review of the antifungal arsenal.

Authors:  Ahmad Mourad; John R Perfect
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-02-19       Impact factor: 2.743

Review 3.  Cryptococcal pleuritis with pleural effusion as the only clinical presentation in a patient with hepatic cirrhosis: A case report and literature review.

Authors:  Jie Wang; Jin-Jing Hong; Piao-Piao Zhang; Mei-Fang Yang; Qing Yang; Ting-Ting Qu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

4.  Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people.

Authors:  Ajibola A Awotiwon; Samuel Johnson; George W Rutherford; Graeme Meintjes; Ingrid Eshun-Wilson
Journal:  Cochrane Database Syst Rev       Date:  2018-08-29

5.  Missed opportunities to identify cryptococcosis in COVID-19 patients: a case report and literature review.

Authors:  Daniel B Chastain; Andrés F Henao-Martínez; Austin C Dykes; Gregory M Steele; Laura Leigh Stoudenmire; Geren M Thomas; Vanessa Kung; Carlos Franco-Paredes
Journal:  Ther Adv Infect Dis       Date:  2022-01-15

6.  Screening for cryptococcal antigenemia using the lateral flow assay in antiretroviral therapy-naïve HIV-positive adults at an Ethiopian hospital clinic.

Authors:  Anton Reepalu; Taye T Balcha; Tadele Yitbarek; Godana Jarso; Erik Sturegård; Per Björkman
Journal:  BMC Res Notes       Date:  2015-11-23

Review 7.  Cryptococcus: Shedding New Light on an Inveterate Yeast.

Authors:  Ghady Haidar; Nina Singh
Journal:  J Fungi (Basel)       Date:  2015-07-14

8.  Clinical and microbiological characteristics of cryptococcosis at an university hospital in China from 2013 to 2017.

Authors:  Lan-Fang Fang; Piao-Piao Zhang; Jie Wang; Qing Yang; Ting-Ting Qu
Journal:  Braz J Infect Dis       Date:  2019-12-20       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.